Babak Tofighi, MD

Upon completing my fellowship in June 2014, I joined the NYU Langone faculty and served as study physician for CTN-0051 (extended-release naltrexone versus buprenorphine opioid treatment, U10 DA013035), and as co-investigator for a National Institutes of Health (NIH)-funded trial, extended-release naltrexone versus oral naltrexone for the treatment of alcohol use disorders in primary care (R01AA020836-01). I was also awarded an NYU Langone Clinical and Translational Science Institute pilot award ($35,000) and a NIH National Center for Advancing Translational Sciences grant ($262,708) to develop mobile health tools supporting patient linkage and retention in buprenorphine treatment. Subsequently, I was awarded a NIH National Institute on Drug Abuse K23 Career Development Award ($969,069) to complete intensive training and clinical studies on leveraging low-cost and ubiquitous technologies to improve access to effective pharmacotherapies for substance use disorders in primary care.